Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2018

Dec 4, 2018

30291_dirs_2018-12-04_bcdd7dee-3035-4161-bb5c-503bd575ded2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2018-12-01

Reporting Person: Guindo Chirfi (EVP Glob. Mkt Acc & Cust Innov)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-12-01 Common Stock F 231 $333.72 Disposed 2119 Direct
2018-12-01 Common Stock M 602 Acquired 2721 Direct
2018-12-01 Common Stock F 178 $333.72 Disposed 2543 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-12-01 Restricted Stock Unit $0 M 602 Disposed 2020-12-01 Common Stock (602) Direct
2018-12-01 Restricted Stock Unit $0 J 566 Disposed 2020-12-01 Common Stock (566) Direct

Footnotes

F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.